SellYourAIData
Get a free valuation Contact

AI Data Deal TrackerDeal brief

×

JAMA Network signs multi-year content agreement with OpenEvidence

OpenEvidence signed a multi-year agreement with the JAMA Network, giving its clinical AI platform access to JAMA, JAMA Network Open and the 11 JAMA specialty journals. Terms were not disclosed.

CAMBRIDGE, Mass., June 5, 2025. OpenEvidence signed a multi-year content agreement with the JAMA Network, a group of peer-reviewed medical journals published by the American Medical Association. The JAMA content will help shape the answers OpenEvidence delivers to its users.1

Terms of the deal

The agreement covers all published content from JAMA, JAMA Network Open and the 11 JAMA specialty journals, including full text and multimedia.1 It is described only as multi-year, with no end date, and no financial terms were disclosed.1

Kirsten Bibbins-Domingo, editor in chief of JAMA, said OpenEvidence had rapidly established itself as a favored resource among clinicians. OpenEvidence's founder, Daniel Nadler, called the JAMA Network a well-known source of high-quality scientific evidence.1

Background

The agreement followed OpenEvidence's February 2025 deal with NEJM Group, the publisher of the New England Journal of Medicine.2 Wiley and Springer Nature announced their own agreements with the company in 2026. The result is that OpenEvidence now licenses content from several of the best-known medical publishers, which it describes as a core part of its product.

The JAMA Network is published by the American Medical Association, so the agreement sits within a professional body's publishing business. The announcement did not say whether the content is used only for retrieval or also to train models.

What it means for data sellers

For sellers in regulated or professional fields, vertical AI companies are active buyers and want authoritative sources. Expect them to want an exclusive-sounding partnership label, and consider whether the seller is comfortable having rivals in the same product. Ask for a defined term and a way to review how the content is used.

How the deal came together

  1. Following the NEJM agreement. OpenEvidence had signed NEJM Group in February 2025 and then approached the JAMA Network.
  2. Full text and multimedia included. The content covers all published material from JAMA, JAMA Network Open and the 11 specialty journals.
  3. Content shapes answers. JAMA content will help shape the answers OpenEvidence gives to its clinician users.
  4. Term left vague. The agreement is described only as multi-year.

Takeaways for companies with data

  • A publisher owned by a professional society can license content while keeping an editorial voice in how it is used.
  • Competing journals often sign with the same vertical buyer within months of each other.
  • Undisclosed prices are the norm in vertical deals, so compare structure, not dollars.

Sources

Every numbered reference above points to an entry here. Figures come from these pages as of the date shown at the top of the article. Where a source reports a number it got from unnamed people, the text says so.

  1. OpenEvidence and the JAMA Network sign strategic content agreement (Newswise, June 2025)
  2. OpenEvidence and NEJM Group sign multi-year content agreement (OpenEvidence, February 2025)

###

About the AI Data Deal Tracker

SellYourAIData tracks publicly reported sales and licenses of data to AI companies, with the price, terms and sources for each. Entries are checked against public reporting and updated as deals change. SellYourAIData was not involved in this deal. To ask what your company's data could sell for, get a free valuation. To report a deal, contact us.